A correspondence in The Lancet argues that the NordICC trial’s modest reductions in colorectal cancer incidence and mortality must be understood in the context of widespread colonoscopy use during the study period.
A correspondence in The Lancet argues that the NordICC trial’s modest reductions in colorectal cancer incidence and mortality must be understood in the context of widespread colonoscopy use during the study period.
Just 42% of invitees showed up; per-protocol, incidence fell 31%. Another trial gutted by apathy, another headline that missed it.